METHAZOLAMIDE (methazolamide) by Applied Medical is clinical pharmacology methazolamide is a potent inhibitor of carbonic anhydrase. Approved for the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such, secondary glaucoma and 1 more indications. First approved in 2026.
Drug data last refreshed 20h ago
CLINICAL PHARMACOLOGY Methazolamide is a potent inhibitor of carbonic anhydrase. Methazolamide is well absorbed from the gastrointestinal tract. Peak plasma concentrations are observed 1 hour to 2 hours after dosing. In a multiple-dose, pharmacokinetic study, administration of methazolamide 25 mg…
Worked on METHAZOLAMIDE at Applied Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Use of Methazolamide to Lower Intraocular Pressure
Safety Evaluation of Aminophylline and Methazolamide